Genos receives CAP Accreditation for Meeting the Highest Standards in Laboratory Practices

SAN FRANCISCO, Feb. 16, 2017 /PRNewswire/ -- Genos, a community for personal genetic discovery and research, today announced that it has received Laboratory Accreditation from the College of American Pathologists (CAP). The CAP Accreditation is presented to laboratories that meet stringent requirements around quality, accuracy and consistency and who demonstrate scientifically rigorous processes.

"Genos is committed to maintaining the highest standards of excellence in laboratory practices. We're honored to be receiving CAP accreditation," said Jill MacAfee, CLS, Director of Laboratory Operations at Genos.

"The CAP accreditation helps demonstrate Genos' commitment to the quality and the accuracy of its data for purposes of its Impact Network that connects researchers with high-quality genomic and phenotypic data," said Arthur Baca, M.D., Ph.D., Laboratory Director of Genos. "With this accomplishment under its belt, Genos will continue to grow its community of sequenced individuals and enable acceleration of research initiatives."

Genos' platform launched in December 2016 to offer exome sequencing and empower individuals to participate in groundbreaking research projects on their own terms through the Impact Network. The initial set of research partners include, NantBioScience, NantKwest, Broad Institute, and the Utah Foundation for Biomedical Research.

About the College of American Pathologists
As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, visit cap.org

About Genos
Genos is a crowdsourcing platform for genomics research and discovery. The company's mission is to break down the barriers to accelerate disease research and medical cures. The Genos community democratizes access to comprehensive personal discovery through DNA, and empowers individuals to retain ownership of their genetic data and consent in the research process. Genos is backed by strategic investors with deep roots in healthcare and technology, and the company's advisors include luminaries in genetics, economics, and consumer technology. For more information, or to help crowdsource cures on your terms, please visit www.genos.co.

Media Contacts

McKenzie Haggard
Method Communications
(801) 461-9773
[email protected]

SOURCE Genos

Related Links

http://www.genos.co